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For most lysosomal storage diseases (LSDs) affecting the CNS, there is currently no cure. The BBB, which lim-
its the bioavailability of drugs administered systemically, and the short half-life of lysosomal enzymes, hamper 
the development of effective therapies. Mucopolysaccharidosis type IIIA (MPS IIIA) is an autosomic recessive 
LSD caused by a deficiency in sulfamidase, a sulfatase involved in the stepwise degradation of glycosamino-
glycan (GAG) heparan sulfate. Here, we demonstrate that intracerebrospinal fluid (intra-CSF) administration 
of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both CNS and somatic 
pathology in MPS IIIA mice. Following vector administration, enzymatic activity increased throughout the 
brain and in serum, leading to whole body correction of GAG accumulation and lysosomal pathology, normal-
ization of behavioral deficits, and prolonged survival. To test this strategy in a larger animal, we treated beagle 
dogs using intracisternal or intracerebroventricular delivery. Administration of sulfamidase-encoding AAV9 
resulted in transgenic expression throughout the CNS and liver and increased sulfamidase activity in CSF. 
High-titer serum antibodies against AAV9 only partially blocked CSF-mediated gene transfer to the brains of 
dogs. Consistently, anti-AAV antibody titers were lower in CSF than in serum collected from healthy and MPS 
IIIA–affected children. These results support the clinical translation of this approach for the treatment of MPS 
IIIA and other LSDs with CNS involvement.
Introduction
Most lysosomal storage diseases (LSDs), particularly those affect-
ing the CNS lack effective therapies beyond supportive treatment, 
resulting, in most cases, in the death of patients at an early age. 
The ultimate goal in the treatment of disorders that affect diffuse 
areas of the CNS is to achieve global distribution of the thera-
peutic agent, while minimizing the delivery-associated risks. The 
BBB, however, constitutes a major obstacle to attaining this goal, 
as it prevents efficient delivery to the CNS of most systemically 
dispensed molecules (1).
Mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo 
syndrome IIIA, is an autosomic recessive LSD caused by the defi-
ciency of sulfamidase (SGSH), a sulfatase involved in the stepwise 
degradation of glycosaminoglycan (GAG) heparan sulfate (HS) 
(2). HS accumulation in the lysosomes of cells is associated with 
progressive, severe neurodegeneration as well as somatic organ 
pathology (2, 3). MPS IIIA patients are first diagnosed at 1 to 
4 years of age, when delayed psychomotor development and behav-
ioral problems become obvious to their parents. This is followed 
by a rapid, progressive loss of cognitive and motor skills (2, 3), 
with death occurring usually by the mid-to-late teenage years (2–4). 
There is no cure for MSP IIIA. A mouse model of the disease 
derived from a spontaneous mutation in the catalytic domain of 
sulfamidase (5) exists and closely resembles the human disease 
in terms of neurodegeneration, neuroinflammation, hepatosple-
nomegaly, and shortened lifespan (6–8).
As with most LSDs, the design of therapeutic strategies for 
MPS IIIA relies on the possibility of cross-correction, based 
on the fact that soluble lysosomal enzymes present in the 
extracellular compartment can be taken up by mannose-6-pho-
spate receptor–mediated (M6PR-mediated) endocytosis into 
affected cells (1). To overcome the limitations imposed by the 
BBB and efficiently provide the brain with enzyme replacement 
therapy (ERT) — the main therapeutic option currently avail-
able for most LSDs — strategies have required the implanta-
tion of delivery devices that allow for repeated administration 
of the therapeutic proteins to the CNS (9). Direct delivery of 
ERT to the CNS is currently being tested in MPS IIIA patients 
(NCT01155778 and NCT01299727, clinicaltrials.gov), but the 
use of permanent intrathecal delivery devices is associated with 
substantial risks and shortcomings. Despite its limitations, 
haploidentical HSC transplantation is another potential thera-
peutic strategy for the treatment of LSDs (10, 11), although no 
clinical success has been reported for MPS IIIA yet. Lentiviral 
vector–mediated transduction of autologous CD34+ HSCs has 
shown therapeutic efficacy in adrenoleukodystrophy (12), and 
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similar studies currently underway for other LSDs will further 
establish the safety and efficacy of this approach, which has 
recently proven successful in treating MPS IIIA mice (13).
In vivo gene therapy offers the possibility of a one-time treat-
ment for MPS IIIA and other inherited diseases, with the pros-
pect of lifelong beneficial effects (14). Adenoassociated virus 
(AAV) vector–mediated gene transfer, in particular, has shown 
promising results as an in vivo gene transfer tool, showing long-
term production of therapeutic proteins in animal models and 
in humans (14–16). Extensive gene delivery to the CNS using 
AAV vectors has been achieved by multiple direct injections into 
the brain parenchyma (17, 18) or by delivery to the cerebrospinal 
fluid (CSF) (19–21). Direct delivery of AAV vectors to the brain 
parenchyma is being clinically explored in MPS IIIA. A phase I/II 
clinical study (NCT01474343, clinicaltrials.gov) was recently ini-
tiated in which AAVrh.10 vectors carrying the sulfamidase and 
sulfatase–modifying 1 (SUMF1) genes are administered to the 
brain through burr holes, a procedure previously established for 
other neurodegenerative disorders (22, 23). Limited vector diffu-
sion from the point of injection required vector administration 
at several sites, making its delivery technically challenging and 
requiring the development of specific surgical procedures (24). 
Alternatively, AAV9, a serotype recently isolated from human tis-
sue (25), has been shown to have broad tropism and to cross the 
BBB after systemic administration (26, 27), reverting the neuro-
logical phenotype of MPS IIIB (28) and MPS IIIA (29) mice. Ter-
minal galactose has been identified as the primary receptor for 
AAV9 (30), and the glycan-binding avidity of these vectors deter-
mines their in vivo fate (31). Additionally, AAV9 vectors delivered 
into the bloodstream efficiently transduce several peripheral tis-
sues, such as liver, heart, and skeletal muscle, demonstrating a 
broad distribution profile (27, 32).
Here, we tested the efficacy of AAV9 vectors directly adminis-
tered to the CSF in reversing the MPS IIIA phenotype in affected 
mice. We hypothesized that the broad biodistribution profile of 
this vector serotype, together with CSF-mediated distribution of 
vectors, would favor widespread transduction of the CNS and 
correction of the disease. Intracisternal administration of AAV9 
vectors carrying the sulfamidase transgene led to increased enzy-
matic activity throughout the brain and liver, resulting in the 
reversal of lysosomal pathology in the CNS and somatic tissues, 
the full correction of behavioral deficits, and a significant exten-
sion of lifespan. Similar widespread distribution of transgene 
expression was observed in a large animal model, in which the 
efficacy of transduction after CSF delivery was greatly impacted 
but not completely blocked by high-titer, preexisting anti-AAV 
antibodies in serum. Our results provide a strong rationale for the 
future clinical translation of AAV9 vector–mediated sulfamidase 
gene transfer to MPS IIIA patients by delivering the therapeutic 
vector through the CSF.
Results
Restoration of enzymatic activity and correction of GAG accumulation 
in the brain of MPS IIIA mice after delivery of AAV9 sulfamidase into 
the CSF. Intracisternal delivery to mice of an AAV9 vector encod-
ing GFP at a dose of 5 × 1010 vector genomes (vg) resulted in 
widespread brain transduction at higher levels compared with 
other AAV serotypes, as indicated by the fluorescence intensity 
throughout the brains of injected mice (Supplemental Fig-
ure 1; supplemental material available online with this article; 
doi:10.1172/JCI66778DS1), with detection of vg in the CNS and 
liver, and low gene copy numbers in other somatic organs (Sup-
plemental Figure 2).
To test the therapeutic efficacy of intra-CSF AAV9 adminis-
tration, a dose-response study was initiated in which 2 doses 
(5 × 109 and 5 × 1010 vg per mouse) of an AAV9 vector encoding 
for murine sulfamidase under the control of the CAG ubiqui-
tous promoter (AAV9-Sgsh) were delivered via intracisternal (i.c.) 
Figure 1
Correction of CNS storage pathology after i.c. delivery 
of AAV9-Sgsh to male MPS IIIA mice. MPS IIIA male 
mice were treated with either 5 × 109 (low dose, LD) or 
5 × 1010 (high dose, HD) vg of AAV9 vector encoding 
for murine sulfamidase (Sgsh) under the control of a 
ubiquitous promoter (CAG) or with 5 × 1010 vg of a non-
coding (MPS IIIA–null) vector as a control. Mice were 
treated at 2 months of age and analyzed 4 months 
later against age-matched WT and untreated MPS IIIA 
mice. (A) Percentage of WT sulfamidase activity and 
(B) GAG content in 5 brain regions analyzed (sections 
I–V illustrated in the diagrams above the plot). Results 
are shown as the mean ± SEM; n = 4–6 animals per 
group. WT sulfamidase activity was set to 100%, which 
corresponds to 3.51 ± 0.06, 4.40 ± 0.54, 5.03 ± 0.17, 
4.31 ± 0.23, and 4.87 ± 0.20 nmol/17 hours/mg of pro-
tein for sections I–V, respectively. *P < 0.05; **P < 0.01, 
and ***P < 0.001 versus MPS IIIA–null.
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Figure 2
Normalization of CNS lysosomal compartment size after intra-CSF delivery of AAV9-Sgsh. (A) LIMP2 immunostaining of lysosomes in different 
brain regions of WT, null, and HD-treated MPS IIIA male mice. Arrows indicate cells with neuronal morphology. Scale bars: 200 μm and 50 μm 
(insets). (B) Histograms depict the corresponding signal quantification in all treatment groups. Results are shown as the mean ± SEM. n = 4–5 
animals per group. *P < 0.05 and ***P < 0.001 versus MPS IIIA–null.
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injection into 2-month-old MPS IIIA mice, an age at which CNS 
pathology is already established (7) and peripheral accumula-
tion of GAGs is also evident (33). Animals were sacrificed after 
4 months of follow up. At the highest dose tested, statistically 
significant increases in sulfamidase activity were observed in all 
brain regions analyzed, reaching 11% to 36% of normal values 
in males (Figure 1A) and 7% to 39% of normal values in females 
(Supplemental Figure 3A), with the highest levels of Sgsh trans-
gene activity recorded in the most rostral parts of the enceph-
alon (sections I–III, Figure 1A and Supplemental Figure 3A), 
distal to the point of AAV9-Sgsh administration. Transgene 
expression resulted in efficient correction of GAG accumula-
tion in several parts of the brain of MPS IIIA mice of both gen-
ders to levels indistinguishable from those of WT littermates, 
with partial reductions achieved in the most caudal portions of 
the encephalon (sections IV and V, Figure 1B and Supplemental 
Figure 3B). A partial, but statistically significant, reduction in 
GAG accumulation was also observed in some, but not all, brain 
areas tested at the low dose of the AAV9-Sgsh vector (section I 
in Figure 1B and sections I and II in Supplemental Figure 3B), 
while no significant increase in sulfamidase transgene levels or 
decrease in GAG accumulation was observed in MPS IIIA mice 
injected with AAV9-null vector (noncoding AAV9 vector used as 
a negative control). Ten to 12 months after a single administra-
tion of AAV9-Sgsh vector, brain GAG content remained normal 
in the treated male and female MPS IIIA mice (Supplemental 
Figure 4, A and B). Moreover, GAG accumulation was com-
pletely corrected in brain sections IV and V, which had previ-
ously shown partial reductions when evaluated 4 months after 
treatment (Figure 1B and Supplemental Figure 3B), suggest-
ing that sustained sulfamidase production over a prolonged 
period of time is necessary to achieve full correction. In agree-
ment with the correction in GAG storage obtained at the high 
vector dose, lysosomal integral membrane protein 2 (LIMP2) 
staining of lysosomes demonstrated a statistically significant 
reduction in lysosomal signal intensity in all brain regions ana-
lyzed (Figure 2). A series of colocalization studies with double 
immunostaining for LIMP2 and specific markers for neurons 
(neuronal nuclei, NeuN), astrocytes (glial fibrilar acidic protein, 
GFAP), and microglia (MAC2 antigen) (Supplemental Figure 5) 
showed that 73% of LIMP2+ cells in untreated MPS IIIA mice 
were neurons. Ultrastructural analysis of the frontal cortex by 
transmission electron microscopy confirmed the reduc-
tion in lysosomal pathology, which was very evident in 
perineuronal glial cells that appeared distended and full 
of large storage vesicles in null-treated MPS IIIA males 
and females, while they had a normal appearance in ani-
mals treated with the high dose of AAV9-Sgsh (Figure 3 
and Supplemental Figure 3C).
Correction of neuroinflammation in MPS IIIA mice follow-
ing AAV9-Sgsh gene delivery. Secondary to the lysosomal 
pathology in neurons and glial cells, the brains of MPS 
IIIA mice are characterized by the presence of extensive 
neuroinflammation (8, 20), a common feature of MPS III 
in humans (34, 35). To evaluate the effect of AAV9-Sgsh 
gene transfer on brain inflammation, MPS IIIA mice 
injected with AAV9-Sgsh or AAV9-null vector were ana-
lyzed in parallel to WT mice 4 months after vector deliv-
ery. Immunohistochemical analysis of tissue sections from 
several brain areas was performed using specific stainings 
for astrocytes and microglia. Immunostaining for GFAP showed 
a statistically significant reversal of astrocytosis in the brain of 
the high dose–treated MPS IIIA mice (Figure 4A). Only partial 
improvement was observed, however, in mice receiving a low dose 
of vector expressing sulfamidase (data not shown). Similarly, 
staining with BSI-B4 lectin, which recognizes membrane-associ-
ated glycoconjugates containing terminal α-D-galactose residues 
present on resting and activated microglia but not on other glial 
cell types (36, 37), showed an absence of microglial infiltration 
in the brains of WT animals or MPS IIIA mice treated with a high 
dose of AAV9-Sgsh, but not in the brains of MPS IIIA mice treated 
with AAV9-null vector (Figure 4B). Also for BSI-B4 staining, par-
tial correction of the disease phenotype was observed at a low 
dose of AAV9-Sgsh (data not shown).
Correction of somatic pathology in affected animals after administration 
of AAV9-Sgsh via the CSF. In agreement with the vector biodistribu-
tion results for AAV9 (Supplemental Figure 2), sulfamidase activ-
ity was detected in liver, reaching levels of approximately 190% of 
the levels observed in WT animals in the males (Figure 5A) and 
20% of the levels observed in WT animals in the females (Sup-
plemental Figure 6A). Sulfamidase activity in serum correlated 
well with the activity in the liver of males (Figure 5B) and females 
(Supplemental Figure 6B), suggesting that the liver was the main 
source of circulating enzymes. Gender differences in the efficiency 
of liver transduction by AAV vectors, including AAV9, are in agree-
ment with previous reports (29, 33, 38).
We evaluated the effect of AAV9-Sgsh i.c. administration on 
somatic organ accumulation of GAGs. Following gene transfer, 
we observed a significant reduction in GAG accumulation in 
most organs of both male and female mice (Figure 5C and Sup-
plemental Figure 6C). At the highest dose tested, MPS IIIA male 
mice showed at least an 85% decrease in GAG content in all tissues 
analyzed, with complete correction (100% reduction) achieved 
in most cases (Figure 5C). In female mice, a decrease in GAGs 
greater than 70% was observed in all tissues except for kidney 
(Supplemental Figure 6C). We confirmed a correction of GAG 
accumulation in most somatic organs in animals of both genders 
sacrificed 10–12 months after administration of a single i.c. dose 
of AAV9-Sgsh (Supplemental Figure 7, A and B). The correction 
of GAG accumulation resulted in a reduction in the size of the 
lysosomal compartment in both genders as soon as 4 months 
after treatment (Figure 5D and Supplemental Figure 6D). 
Figure 3
Frontal cortex ultrastructure. Transmission electron microscopy illustrating the 
reduction of lysosomal pathology in cells of the frontal cortex following treat-
ment with HD AAV9-Sgsh. Correction was very evident in the perineuronal 
glial cells, in which large electrolucent vacuoles (arrows) were detected in 
null-injected MPS IIIA mice but not in healthy (WT) or AAV9-Sgsh–treated 
male mice. 1, neuron; 2, perineuronal glial cell. Scale bars: 2 μm.
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These results suggest that, although lower than in males, serum 
levels of sulfamidase activity achieved in females animals treated 
with the high dose of vector were sufficient to correct somatic 
disease. At the low dose of AAV9-Sgsh, we observed a statistically 
significant partial reduction in GAG accumulation in most 
somatic organs tested (Figure 5C and Supplemental Figure 6C). 
As expected from the results in the high vector dose cohort, we 
found a lesser extent of disease correction at the low dose in 
females than in males.
Functional correction of MPS IIIA disease by CSF administration of 
AAV9-Sgsh. We assessed the impact of intra-CSF AAV9-Sgsh vec-
tor administration on behavior with the open field test, which 
evaluates the general locomotor and exploratory activity of 
mice in unknown surroundings. AAV9-Sgsh–treated MPS IIIA 
mice and controls were evaluated 4 months after gene deliv-
ery together with age-matched WT mice. Untreated and AAV9-
null–treated MPS IIIA mice displayed reduced exploratory 
activity compared with healthy mice in terms of total distance 
traveled, number of lines crossed, and number of rearings on 
their hind legs (Figure 6, A–C). Intra-CSF delivery of 5 × 1010 vg 
of AAV9-Sgsh to MPS IIIA mice completely corrected the behav-
ioral deficits, while no therapeutic effect was observed at the 
low vector dose, suggesting that improvement of CNS function 
requires considerable correction of lysosomal pathology. Fur-
thermore, MPS IIIA animals receiving the high vector dose lived 
significantly longer than untreated MPS IIIA mice. Treated 
males showed a median survival of 24 months, compared with 
a 16.2-month median survival for MPS IIIA untreated males; 
P = 0.0132 (Figure 6D). Similarly, untreated MPS IIIA female 
mice had a median survival of 12.3 months versus 20-month 
survival for MPS IIIA females treated with AAV9-Sgsh vector 
(P = 0.0085) (Supplemental Figure 8). Median survival for 
healthy male and female littermates was 26.4 and 27 months, 
respectively. The normalization of behavioral responses and the 
greater survival of treated MPS IIIA mice further demonstrate 
the therapeutic efficacy of intra-CSF AAV9-Sgsh delivery and 
support the translation of this approach to the clinic.
Widespread vector biodistribution following CSF delivery of AAV9 
vectors in a large animal model. The validation in large animal spe-
cies of approaches proven successful in rodents is instrumental 
for moving gene therapies forward into humans. To evaluate 
vector biodistribution in an animal species with a clinically rel-
evant brain size, we delivered 2 × 1013 vg of AAV9-GFP into the 
CSF of healthy beagle dogs via cisterna magna injection. Vector 
was delivered in a total injected volume of 1 ml; Dogs 1 and 2 
received the vector through an infusion pump set at 100 μl per 
minute over a period of 10 minutes and Dogs 3 and 4 as a bolus 
(injection in under 15 seconds) (Table 1). Intracisternal vector 
delivery was well tolerated, without alterations in hematolog-
ical or biochemical parameters (data not shown). Total white 
cell counts and protein content in CSF samples also remained 
within normal reference values (Supplemental Table 1). GFP 
immunodetection in brain sections demonstrated expression 
of the transgene in widespread areas of the CNS (Figure 7A), 
which was confirmed by detection of vector genomes in all 
brain areas analyzed in the 4 dogs (Table 2). Vector transduction 
was detected in regions close to the cisterna magna, such as the 
medulla oblongata and the pons, but also in areas distant to the 
injection site, such as the frontal cortex (Figure 7A and Table 2). 
In several brain regions, the number of GFP+ cells was greater in 
areas closer to the brain surface, showing a diffuse horizontal 
pattern of distribution with respect to the leptomeninges, an 
observation consistent with CSF-mediated diffusion of vectors 
from the surface toward deeper areas (Figure 7A). A multifo-
cal pattern of GFP+ cells was also observed in regions of the 
cerebral cortices, with groups of transduced cells occupying the 
whole gray matter and reaching the deepest laminae (see occip-
ital and frontal cortices in Figure 7A), and their positive axons 
were observed in the adjacent white matter (not shown). The 
morphology of most transduced cells was typical of neuronal 
cells (arrows, Figure 7A). Immunostaining with specific cell 
markers confirmed the majority of transduced cells as being 
neurons, with transgene expression in scattered astrocytes and 
no detectable transduction of microglia (Supplemental Figure 
9). No differences were observed in transduction efficiency 
(Figure 7B) or vector distribution (Table 2) in relation to the 
infusion rate. As observed in mice, administration of AAV9 into 
the CSF resulted in the detection of vector genomes in the liver 
(Table 2) and transduction of 3% to 5% of hepatocytes (Figure 7C) 
and low gene copy numbers in other organs except for the 
spleen (Table 2).
Increased sulfamidase activity in the CSF of dogs following delivery 
of sulfamidase-encoding AAV9 vectors. A therapeutic option for 
MPS IIIA currently under clinical testing consists of the direct 
delivery of recombinant sulfamidase to the CSF for its distribu-
tion throughout the CNS (NCT01155778 and NCT01299727, 
clinicaltrials.gov). The approach demands the implantation of 
a permanent intrathecal delivery device to allow for repeated 
administrations of the enzyme, a requirement imposed by the 
short half-life of sulfamidase (39). In contrast, our approach 
aims at providing a continuous endogenous source of sul-
famidase upon a single administration. We delivered an AAV9 
vector encoding for human sulfamidase (AAV9-SGSH) to the 
cisterna magna of healthy beagle dogs (Dogs 5 and 6), scaling 
up the therapeutic dose used in mice to 2 × 1013 vg, based on 
the body weight of mice compared with dogs (Table 1). Sul-
famidase activity measured in the CSF rose above baseline levels 
1 week after administration, peaking around 2 to 3 weeks and 
decreasing thereafter (Figure 8A). The increase in sulfamidase 
activity observed following AAV9-SGSH vector delivery coin-
cided with the detection of mononuclear cells, predominantly 
lymphocytic, in the CSF (Figure 8A and Supplemental Table 1), 
a phenomenon previously documented in dogs when nonspe-
cies-specific transgenes were used (18). The number of inflam-
matory cells progressively dropped concomitantly with the 
loss of sulfamidase activity (Figure 8A). Despite the inflam-
matory reaction, treated dogs remained clinically well and, in 
agreement with the fact that 3 months after delivery CSF sul-
famidase activity remained above baseline levels in both ani-
Figure 4
Correction of neuroinflammation following AAV9-Sgsh treatment.  
(A and B) Immunostaining for the astrocyte marker GFAP (A) and for 
the microglial marker BSI-B4 (B) in sections of frontal, parietal, and 
occipital cortex, superior colliculus, and thalamus from healthy (WT) 
male mice, and null- and HD-treated MPS IIIA male mice analyzed 
4 months after gene delivery. Scale bars: 50 μm and 20 μm (insets). 
Histograms represent the signal intensity in each area for each treat-
ment group. Results are shown as the mean ± SEM. n = 4–5 animals 
per group. **P < 0.01; and ***P < 0.001 versus MPS IIIA–null.
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mals (Figure 8A), the expression of human sulfamidase was 
detectable throughout different areas of the CNS, as well as in 
the peripheral nervous system (PNS) and somatic tissues (Sup-
plemental Figure 10A).
Next, we administered 2 × 1013 vg of an AAV9 vector encoding 
for canine sulfamidase (AAV9-SGSH) to the cisterna magna of 
3 additional dogs (dogs 7–9, Table 1). A clear increase in sul-
famidase activity was detectable in the CSF of all 3 dogs as soon 
as 1 week after vector administration (Figure 8B). Similarly to 
the kinetics of transgene expression observed in dogs injected 
with the human transgene, activity peaked 2–4 weeks after vec-
tor delivery, but contrary to what was observed in animals receiv-
ing vectors expressing human sulfamidase, transgene expres-
sion was maintained at high levels throughout the 3-month 
Figure 5
Correction of MPS IIIA somatic pathology after CNS-directed gene therapy. (A) Percentage of normal liver sulfamidase activity in male MPS IIIA 
mice 4 months after intra-CSF delivery of 5 × 109 (LD) or 5 × 1010 (HD) vg of AAV9-Sgsh or 5 × 1010 vg of a noncoding vector (MPS IIIA–null) as a 
control. WT sulfamidase activity was set to 100% and equaled 12.77 ± 0.85 nmol/17 hours/mg of protein. (B) Sulfamidase activity was monitored 
periodically in serum from all experimental groups during the 4-month follow-up period. Activity averaged 160% of that observed in WT mice 
(27.66 ± 1.47 nmol/17 hours/ml of serum) at the highest dose tested and was practically undetectable in untreated, null-treated, and LD-treated 
MPS IIIA animals. (C) Quantification of GAG content in liver, heart, lung, spleen, kidney, and urinary bladder in all experimental groups. Results 
are shown as the mean ± SEM; n = 5–8 animals per group. *P < 0.05 and ***P < 0.001 versus MPS IIIA–null. (D) LAMP1 immunostaining of lys-
osomes in liver, heart, lung, and urinary bladder demonstrating enlargement of the lysosomal compartment in affected animals (MPS IIIA–null) 
and a reduction in lysosomal pathology in animals treated with HD AAV9-Sgsh vector. Scale bars: 100 μm and 20 μm (insets). p.i., post injection.
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follow-up (observation ongoing). Moreover, white blood cells 
counts and CSF protein levels remained within normal range 
at all times (Supplemental Table 1), excluding the presence of 
an inflammatory process in the CNS of any of the dogs. Clearly, 
these results demonstrate that the loss of transgene expression 
observed in Dogs 5 and 6 was due to the use of a nonspecies-spe-
cific transgene and that achieving long-term, stable levels of sul-
famidase in the CSF of dogs is feasible.
Comparison of i.c. and i.c.v. CSF delivery of AAV9 vectors. The 
cisterna magna is easily accessible in mice and dogs, and cis-
ternal puncture is a routine procedure in veterinary medicine. 
Intracisternal administration is not, however, standard in 
clinical practice in pediatric patients. We therefore performed 
a comparative study in which AAV9-GFP vectors were deliv-
ered into the CSF by either i.c. injection (Dog 10) or unilateral 
i.c.v. administration (Dogs 11 and 12) (Table 1) by a technique 
commonly used in pediatric neurosurgery (40). For i.c.v. vec-
tor delivery, a catheter was placed in the largest lateral ven-
tricle, and 1 ml of vector solution was delivered within a few 
seconds (Figure 9A). The procedure was well tolerated in both 
animals dosed through this technique, and total white cell 
counts and protein content in CSF samples remained within 
normal range (Supplemental Table 1). In i.c.v.-injected dogs, 
the choroid plexus epithelium and ventricle lining ependi-
mocytes were efficiently transduced in the injected hemi-
sphere (Figure 9B), but positivity for GFP was also observed 
in the contralateral ventricle (data not shown). In both i.c. 
and i.c.v.-injected dogs, leptomeningeal cells showed strong 
immunoreactivity against GFP (Figure 7A and Figure 9B), 
with an estimated 75%–100% of leptomeningeal cells transduced 
in the cerebellar and caudal cerebral areas, decreasing slightly 
toward the most rostral areas of the brain. In the cerebral cortex, 
positive cells showed the same diffuse horizontal and multifocal 
patterns of distribution observed after i.c. delivery and spanned 
through all cortical layers (Figure 9B). Side-by-side analysis of 
vector distribution and transgene expression in the CNS and 
somatic organs were not suggestive of major differences in 
the vector transduction profile with either route of delivery 
(Figure 10). Efficient transduction of the trigeminal and dor-
sal root ganglia of the PNS was also observed (Figure 10B). 
Together, these results show that it is possible to achieve wide-
spread AAV9 vector distribution and transgene expression 
following i.c.v. delivery to the CNS (Supplemental Figure 11) 
and PNS of large animals using a clinically approved surgical 
procedure, thus making the i.c.v. route suitable for the clinical 
translation of our approach. These results also show that the 
efficiency of CNS transduction after i.c.v. and i.c. vector deliv-
ery in a large animal model is comparable.
Asymmetrical distribution of AAV-neutralizing antibodies across the BBB. 
Serum- neutralizing antibodies (NAbs) against AAVs are highly 
prevalent in humans (41). NAbs can profoundly impact the 
efficiency of vector transduction after systemic administration 
(42–44), and several approaches are currently under investi-
gation to overcome this limitation (45, 46). Due to the pres-
ence of the BBB, CSF concentrations of immunoglobulins are 
lower than those in plasma. There is evidence, however, sug-
gesting that the function of the BBB is altered in some LSDs 
(47), although no data are available on MPS IIIA individuals. 
To evaluate the prevalence of NAbs against AAV in the CSF of 
healthy subjects and MPS IIIA–affected individuals, matched 
serum and CSF samples were collected from subjects of pedi-
atric age (reflecting the age for a therapeutic intervention) and 
Figure 6
Correction of behavioral defi-
cits and prolonged survival fol-
lowing intra-CSF AAV9-Sgsh 
delivery. Naive-tested WT, 
untreated, and treated MPS 
IIIA male mice were evaluated 
by the open field test 4 months 
after i.c. delivery of 5 × 109 (LD) 
or 5 × 1010 (HD) vg of AAV9- 
Sgsh or 5 × 1010 vg of AAV9-
null vectors. Data correspond to 
the locomotor and exploratory 
activity recorded during the 
first 3 minutes and are repre-
sented as the mean ± SEM of 
10 to 15 animals per group. (A) 
Total number of lines crossed, 
(B) total distance traveled, and 
(C) total number of rearings 
on the hind limbs. *P < 0.05, 
**P < 0.01, and ***P < 0.001 
versus MPS IIIA–null. (D) 
Kaplan-Meier survival analy-
sis in WT (n = 23), MPS IIIA– 
(n = 12), and HD-treated (n = 8) 
MPS IIIA male mice. P = 0.013 
for untreated versus AAV9-
treated MPS IIIA mice.
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were tested using an in vitro assay previously described (42). 
Anti-AAV2 and anti-AAV9 NAbs were present in serum at a wide 
range of titers (Table 3), with anti-AAV2 titers being higher 
than anti-AAV9 titers, which is consistent with previous studies 
on the prevalence of antibodies reacting against these AAV sero-
types (41). In CSF samples, NAbs were also detected, but titers 
were consistently lower than those of matched serum samples. 
Similarly, in MPS-IIIA–affected subjects, NAbs in serum were 
higher than in the CSF, suggesting that the disease did not alter 
BBB permeability for circulating immunoglobulins. With the 
limitation of the small number of matched serum-CSF pairs 
available, NAb titers seemed to increase with age (48, 49).
In healthy dogs, the administration of AAV9 vectors into the 
CSF resulted in robust systemic humoral responses against the 
AAV9 capsid (Table 4). All dogs presented undetectable levels 
of anti-AAV9 NAbs in serum and CSF at baseline. As expected, 
serum titers rose quickly after exposure to vector, and 8 days after 
administration, all animals had NAb titers greater than 1:1,000. 
However, in the absence of inflammation, matched CSF sam-
ples uncontaminated with blood were negative or had titers less 
than 1:10, confirming the asymmetrical distribution of NAbs 
across the BBB. In Dogs 5 and 6, which had signs of inflamma-
tion of the CNS, NAb titers in the CSF reached 1:100–1:1,000 
(Supplemental Figure 10B).
Impact of humoral immunity on the efficiency of CNS transduction 
through CSF vector delivery. Finally, we investigated to what 
extent the presence of preexisting immunity against AAV influ-
enced the efficiency of intra-CSF AAV9-mediated gene transfer 
to the CNS. Two beagle dogs (Dogs 13 and 14) were immu-
nized against AAV9 by i.v. injection of 1.2 × 1012 vg of AAV9-
null vector. Thirty days following immunization, the animals 
received 2 × 1013 vg of AAV9-GFP via i.c. delivery (Table 1). The 
animals were sacrificed 8 days after vector delivery, and vector 
transduction efficiency was evaluated. Following immunization, 
serum anti-AAV9 NAb titers rose to greater than 1:1,000 in both 
dogs; in the CSF, NAb titers were considerably lower, remaining 
around 1:1 to 1:3.1 (Dogs 13 and 14, day 0; Table 4), an NAb 
titer sufficient to block vector transduction following 
systemic delivery (43, 44). Despite the high stringency 
of the model we used to assess the impact of NAbs 
on CNS transduction (i.e., serum NAb titers greater 
than 1:1,000) and given that only a small proportion 
of humans will present with very high anti-AAV9 
antibody titers (41), GFP expression was detected 
throughout the CNS, particularly in the leptome-
ninges in both injected animals (Figure 11, A and B), 
though at what seemed to be slightly lower levels 
than in naive animals. Quantification of vector copy 
numbers and GFP mRNA showed vector genomes and 
transgenic expression in 70% to 95% of CNS samples 
collected from preimmunized dogs (Figure 11B). In 
addition, the PNS was also efficiently transduced 
in preimmunized animals following CSF delivery 
(Figure 11B), while the transduction of peripheral tis-
sues was completely blocked (Supplemental Figure 12), 
as expected, due to the high NAb antibody titers in 
the serum of these animals (Table 4). These data sug-
gest that humoral immunity against AAV may lower 
the efficacy of AAV gene transfer upon delivery of 
vector into the CSF, however, significant NAb titers 
in the CSF and a decrease in CNS transduction would only be 
observed when circulating NAb titers are very high.
Discussion
Here, we report the efficacy of what we believe to be a novel gene 
therapy approach based on direct CSF administration of AAV9 
sulfamidase for the treatment of MPS IIIA. The combination of 
this route of delivery, considerably less invasive than the direct 
injection of AAV vectors into the brain parenchyma, with the 
widespread transduction of AAV serotype 9 vectors mediates 
full histopathological and functional correction of not only 
central, but also somatic, pathology in MPS IIIA mice. A single 
administration of vector directly into the CSF of MPS IIIA mice 
resulted in widespread transduction of the CNS, with leakage of 
vector into the bloodstream and correction of somatic disease 
in both male and female animals. This translated into a marked 
improvement in brain function and survival of the animals that 
was indistinguishable from their healthy littermates. Our study 
represents what we believe to be the first report of the combined 
treatment of CNS and somatic disease in MPS IIIA with a single 
administration of vector to the CNS.
The use of AAV9 vectors delivered i.v. to target the brain has 
been previously described (26–28). AAV9 is among the few sero-
types of AAV able to cross the BBB (26), making it an ideal tool 
for targeting the brain. However, the approach has several lim-
itations. First, there is the need for high vector doses to achieve 
correction of CNS pathology (27, 28), doses that must be con-
siderably higher (7.5–20–fold, depending on the study) than 
those tested here; second, AAV vectors delivered systemically 
may be neutralized by anti-AAV antibodies (42–44), which are 
highly prevalent in humans (41); finally, systemic exposure to 
high doses of AAV vectors may trigger the activation of CD8+ T 
cell responses directed against the viral capsid in a dose-depen-
dent manner (16, 42, 50, 51). Direct delivery of AAV vectors into 
the CSF can potentially overcome these limitations, allowing 
for a lower therapeutic vector dose, limited exposure of vector 
to serum anti–AAV NAbs (vide infra), and potentially achieving 
Table 1
Summary of the experimental treatment and time of follow up for each dog
Dog no. Route of  Speed of  Transgene Follow up 
 administration infusion  
1 IC Slow GFP 8 days
2 IC Slow GFP 8 days
3 IC Fast GFP 8 days
4 IC Fast GFP 8 days
5 IC Fast Human sulfamidase 90 days
6 IC Fast Human sulfamidase 90 days
7 IC Fast Canine sulfamidase 90 days
8 IC Fast Canine sulfamidase 90 days
9 IC Fast Canine sulfamidase 90 days
10 IC Fast GFP 8 days
11 ICV Fast GFP 8 days
12 ICV Fast GFP 8 days
13A IC Fast GFP 8 days
14A IC Fast GFP 8 days
All dogs received an intra-CSF dose of 2 × 1013 vg of AAV9 vectors. AFor preimmunized 
dogs, the “0” time point corresponds to samples obtained before i.c. administration, i.e. 
30 days after immunization with i.v. delivery of 1.2 × 1012 vg of AAV9-null vector.
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therapeutic efficacy at vector doses below those associated with 
unwanted anticapsid cytotoxic T cell responses.
Different AAV vector serotypes have been tested after intra-CSF 
delivery in LSD animal models with variable outcomes. In most 
cases, widespread CNS vector distribution was reported (19–21), 
with the exception of i.c.v. administration of AAV4 that resulted in 
the exclusive transduction of ependyma (52). In our hands, how-
ever, AAV9 clearly outperformed all other AAV serotypes tested in 
transduction efficiency throughout the CNS. Most importantly, 
none of those studies reported a correction of peripheral disease 
after CNS-targeted delivery. The profile of AAV9 distribution 
observed in both species analyzed, with significant brain and liver 
transduction after CSF delivery, would result from the combina-
tion of CSF-mediated vector distribution throughout the CNS 
and the unique properties of AAV9, a vector with well-documented 
ability to cross vascular barriers (26, 27).
A noteworthy observation of our study was the existence of gen-
der differences in response to the intra-CSF delivery of AAV9-Sgsh. 
While vector genome copy numbers, sulfamidase activity levels, 
and long-term disease correction (assessed 10–12 months after 
delivery) were very similar in the brains of treated MPS IIIA males 
and females, clear differences were observed in the periphery. 
Most strikingly, the levels of sulfamidase activity achieved in the 
liver and serum of females of the high-dose cohort were lower 
than those observed in males dosed with an equal amount of vec-
tor. We and others have previously reported gender differences 
Figure 7
Widespread CNS and liver transduction after i.c. delivery of AAV9 vectors to dogs. Healthy adult beagle dogs (Dogs 1–4) received a dose of 
2 × 1013 vg of AAV9 vectors encoding for the GFP marker, and transgene expression was analyzed by immunohistochemistry 8 days after 
administration. (A) Widespread CNS transgene expression in Dog 1 following i.c. delivery of AAV9 vectors. Sections correspond to regions 
scattered throughout the CNS (see diagram). FC, frontal cortex; PC, parietal cortex; OC, occipital cortex; Cer, cerebellum; Hc, hippocampus; 
Rin, rhinencephalon; Ht, hypothalamus; P, pons; MO, medulla oblongata; SC, spinal cord. (B) Comparison of the effect of the i.c. infusion rate on 
vector distribution. Vectors were delivered using an infusion pump over the course of 10 minutes (Dogs 1 and 2, slow) or in a bolus (Dogs 3 and 4, 
fast), and transduction in different CNS areas was compared through quantification of signal intensity in 2 images per area per dog in brain 
sections immunostained for GFP. Color code corresponds to μm2 of positive area. (C) Liver transduction after i.c. delivery of AAV9 vectors. As a 
consequence of vector leakage into the circulation, 3%–5% of hepatocytes expressed GFP. Scale bars: 500 μm for FC, PC, OC, Rin, Ht, P, MO, 
SC, and liver (100 μm for insets), and 100 μm for Cer and Hc.
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in liver transduction by AAV vectors of serotypes 2, 5, 8, and 9 
in mice and dogs (33, 38, 53), which are independent of the pro-
moter or mouse strain used (29, 33, 38) and which do not affect 
the transduction of nonhepatic tissues (29, 38) and seem to be 
androgen driven (38). Despite the lower level of transduction 
achieved in treated MPS IIIA females receiving the high dose of 
vector, sulfamidase activity levels in serum averaged 20% of those 
found in WT mice during a 4-month follow-up period, and this 
was sufficient to achieve long-term correction of pathological 
accumulation of GAGs in most somatic organs and considerably 
prolonged survival. There seems to be a very low threshold of 
activity in LSDs above which lysosomal enzymes are capable of 
coping with substrate influx and avoiding accumulation. Preclin-
ical studies of ERT or gene therapy approaches in other forms of 
MPS have demonstrated that low levels of circulating enzyme (as 
low as 5% of normal) can mediate the correction of GAG accumu-
lation in most somatic tissues (54, 55). This low enzymatic activity 
requirement for disease correction is further supported by clinical 
evidence; a clear correlation between MPS IIIA clinical manifesta-
tions and the patients’ underlying mutations have recently been 
demonstrated in a large cohort of MPS IIIA–affected individuals 
(2). This report identified carriers of mutations associated with a 
certain degree of residual enzymatic activity (3) that showed a rel-
atively mild disease phenotype, suggesting that low, constant lev-
els of activity are enough to change the clinical course 
of the disease. Overall, our results emphasize the 
importance of including female cohorts when assess-
ing the efficacy of AAV-based gene therapy approaches 
for inherited diseases that affect both genders.
In an effort to translate MPS IIIA results to the 
clinic, we assessed the feasibility and tolerability of our 
approach in a large animal model. We first demon-
strated widespread CNS transduction after i.c. admin-
istration of AAV9-GFP vectors in naive, healthy dogs. 
Vector doses were scaled up from the doses used in 
mice and resulted in vector dissemination to the CNS, 
but also to the liver, confirming the results obtained in 
the murine model of MPS IIIA. We next used an i.c.-de-
livered AAV9 vector encoding for human sulfamidase, 
currently under clinical development. Following vec-
tor delivery, an increase in sulfamidase activity was 
measured in the CSF. In this experiment, transgenic 
expression was short lived due to the development of 
what appeared to be an immune response against the 
nonspecies-specific human transgene, which was not 
observed in mice when the species-specific transgene 
was used. This finding can be explained based on the 
differences in the amino acid sequence of the human 
versus canine sulfamidase protein (94% homology). 
Immune responses against the nonspecies-specific 
transgene were also observed in rhesus macaques 
undergoing hepatic gene transfer with AAV vectors 
encoding for human coagulation factor IX (FIX) 
(56–58) and in MPSI and IIIB dogs following CNS 
gene transfer with human transgenes (18). Impor-
tantly, at least in the context of hemophilia B, immune 
responses against the human transgene observed in 
nonhuman primates did not predict the outcome in 
humans, as no humoral or cellular immunity against 
the FIX transgene was documented in clinical trials, 
even in patients carrying null mutations in the endogenous FIX 
gene, who are generally at higher risk of mounting an immune 
responses against the WT protein (16, 42). It is worth mention-
ing that greater than 90% of the mutations causing MPS IIIA 
described so far are missense mutations and that recent studies 
on a large cohort of MPS IIIA patients showed that greater than 
98% of subjects were carriers of at least 1 allele corresponding to 
a missense mutation and were therefore expected to have some 
degree of tolerance to sulfamidase (2). The confirmation that the 
loss of transgenic expression observed in Dogs 5 and 6 was due to 
the use of a nonspecies-specific transgene comes from the dogs 
that were administered vectors encoding for canine sulfamidase. 
In these animals, the initial kinetics of transgenic expression and 
the levels of sulfamidase activity in the CSF were similar to those 
observed in dogs injected with the human transgene. However, in 
dogs expressing the canine transgene, activity remained at high 
levels, and no increase in white blood cell counts or CSF protein 
levels was observed throughout the 3-month follow-up period, 
excluding the presence of CNS inflammation in these dogs. Hence, 
this study demonstrates that achieving long-term, stable levels of 
sulfamidase production following CSF delivery of AAV9 vectors 
is feasible, as shown here for what we believe to be the first time 
in a large animal. It also highlights the importance of carefully 
evaluating the choice of the use of a transgene in preclinical stud-
Table 2
Vector biodistribution following i.c. delivery of AAV9-GFP vectors to dogs
 Vector genomes/diploid genome 
 Slow  Fast 
 Dog 1 Dog 2 Dog 3 Dog 4
CNS
Rhinencephalon 1.82–3.4 1.62–5.86 15.36 1.72–4.2
Dorsal frontal cortex 5.85–6.58 2.36–3.34 2.20–3.05 5.4–6.2
Medial frontal cortex 3.82 1.67 1.49 1.24
Dorsal parietal cortex 1.07 0.03 1.68 1.93
Lateral parietal cortex 3.07 6.93 0.6 6.2
Temporal cortex 2.14 2.6 0.43 3.26
Piriform lobe 16.43 3.98 3.98 11
Hippocampus 0.82 1.49 3.75 0.86
Pons 3.25 0.31 0.1 3.37
Cerebellum 0.27–0.4 0.32–0.78 2–3.6 0.18–0.38
Medulla oblongata 0.3–1.17 1.22 NA 2.42–7.12
C3–C6 NA 0.34–0.51 10.39 7.22
Somatic tissues
Liver 4.72–6.61 1.75–1.52 4.13–7.77 2.73–1.54
Heart 0.09 0.05 0.24 0.01
Lung 0.22 0.12 0.48 0.04
Spleen 4.12 1.68 17.73 3.24
Pancreas 0 0 0.01 0
Intestine 0.07 0.01 0.03 0.02
Kidney 0.22 0.49 0.25 0.26
Skeletal muscle 0.23 0.13 0.25 0.04
Gonads 0.03 0.01 0.12 0.02
Cervical LN 2.9 1.82 3.69 0.01
Popliteal LN NA NA 0.42 0.56
Vector genome copy numbers were determined in different brain areas and in several 
somatic organs in dogs receiving slow or fast infusions of 2 × 1013 vg of AAV9-GFP 
vectors to the cisterna magna (Dogs 1–4). For those specimens for which 2 samples 
were available, both values are provided. NA, not available.
Downloaded on August  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/66778
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013 3265
ies in order to avoid overestimating potential immunogenicity of 
the therapeutic transgene itself. Preclinical studies of intrathecal 
delivery of a recombinant enzyme (39, 59–61), now being trans-
lated to humans (NCT01155778 and NCT01299727, clinicaltri-
als.gov), confirm that an increase in sulfamidase levels in CSF can 
be effective in counteracting the pathological changes associated 
with MPS IIIA and further support the rationale of our study.
While we showed safety and efficacy in MPS IIIA mice and 
evidence of widespread transgenic expression in dogs using 
i.c. delivery of AAV9 vectors, the injection procedure used is 
uncommon in the clinic due to the risk of complications derived 
from the proximity of the cisterna magna to vital centers. We 
therefore focused on the i.c.v. route of administration, as it is 
a safer alternative for the delivery of AAV9-SGSH to the CSF 
in humans. Ventricular access to the CSF through the lateral 
ventricle, or ventriculostomy, is an important diagnostic and 
therapeutic tool for neurosurgeons, with more than 40,000 pro-
cedures performed per year in the United States (62). Using the 
i.c.v route for vector delivery, we achieved a very similar pattern 
of vector distribution throughout the CNS, the PNS, and other 
body organs and systems to that achieved in the 7 dogs previ-
ously dosed via the i.c. route and in which transgenic expres-
sion was measured. For both the i.c. and i.c.v. routes, efficient 
transduction was detected from the most rostral part of the 
encephalon (frontal cortex) to the end of the spinal cord (cauda 
equina), and the pattern suggested CSF-driven penetration of 
vector from the CNS surface to deeper areas.
An alternative route of CSF delivery is via lumbar puncture. 
Although this is a common clinical procedure, limited distribu-
tion of products in widespread CNS areas is achieved through 
this route. Preclinical data in pigs show that AAV9-derived gene 
expression following local lumbar intrathecal administration 
remains restricted to the areas of injection and that widespread 
spinal cord transduction requires several administrations of vec-
tor at the cervical, thoracic, and lumbar regions, suggesting that 
vector penetration occurs mostly in the vicinity of the catheter 
tip used for delivery (63). Global CNS gene delivery following 
intrathecal AAV administration has been documented in cyn-
omolgus macaques, a nonhuman primate species of small size 
(~3–7 kg), using self-complementary AAV vectors diluted in a 
hyperosmotic buffer (64); while the study provides evidence that 
the approach is potentially feasible, detailed confirmatory stud-
ies in larger animal models are needed. In humans, a comparison 
of aminoglycoside therapies after CSF administration indicates 
that lumbar delivery results in high aminoglycoside concentra-
tion in lumbar CSF, but rather low concentrations in ventricular 
CSF, whereas instillation in the lateral ventricles results in high 
ventricular and lumbar CSF concentrations (65). The results of 
these studies confirm the concept of unidirectional flow of CSF 
and suggest that i.c.v. administration of products may result in 
the most widespread distribution of drugs within CSF-contain-
ing compartments (63, 65).
Finally, our study also examined the prevalence of anti-AAV 
NAbs in the serum and CSF of humans and their possible 
impact on vector-mediated CNS transduction following deliv-
ery to the CSF. To the best of our knowledge, we showed, for the 
first time, that MPS IIIA subjects carry anti-AAV antibodies in 
serum and CSF at levels similar to those in healthy individuals, 
indicating that despite the pathological accumulation of GAGs, 
the BBB is still intact, a result consistent with the lack of CNS 
correction through systemic ERT in this disease. Importantly, 
NAb titers were consistently lower in the CSF than in serum, 
both in humans and in dogs immunized through i.v. AAV vector 
administration. Despite being detectable, NAb titers in the CSF 
did not completely block AAV vector transduction in the brain, 
a result in contrast to previously published results (66) and in 
agreement with a recent study that explored CNS transduction 
following intra-CSF delivery in nonhuman primates with low 
serum NAb titers (64). Altogether, our study demonstrates that 
CNS gene transfer is possible in the presence of preexisting anti-
capsid antibodies. This observation, in conjunction with the 
low prevalence of NAbs against AAV in healthy and MPS IIIA–
affected children, suggest that most patients would be eligible 
for enrollment in AAV vector gene transfer trials targeting the 
CNS via i.c.v. vector delivery. Conversely, as demonstrated here, 
NAbs will likely block peripheral organ transduction, possibly 
requiring ERT in combination with gene transfer to achieve 
whole body correction of MPS IIIA.
One final question remains regarding whether brain function 
can be restored simply by providing the missing enzyme, taking 
into account that for most LSDs, clinical signs appear once some 
degree of tissue damage has already occurred. We and others 
have determined that by 2 months of age, MPS IIIA mice have 
established pathology in brain and somatic organs, with signifi-
cant accumulation of GAGs and lysosomal distention (7, 33). 
In MPS IIIA mice 6 to 18 weeks of age, repeated intra-CSF ERT 
achieved partial, but not complete, reversion of the disease phe-
Figure 8
Detection of sulfamidase activity in the CSF following intra-CSF delivery 
of AAV9 vectors. (A and B) Follow up of sulfamidase activity in the CSF 
of healthy adult beagle dogs following i.c. administration of 2 × 1013 vg of 
AAV9 vectors encoding for human (Dogs 5 and 6) (A) or canine (Dogs 
7–9) (B) transgenes. Sulfamidase activity (filled symbols) and white cell 
counts (open symbols) are depicted in the same graph. Basal CSF sul-
famidase activity was quantified in CSF samples from 10 untreated, 
healthy beagle dogs and fell below detection limits. ACT, activity.
Downloaded on August  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/66778
research article
3266 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013
tive of full phenotypic reversal, while untreated MPS IIIA mice 
showed behavioral deficits as soon as 10 weeks of age (67).
In summary, intra-CSF delivery of AAV9 vectors led to transgenic 
expression in widespread areas of the CNS, PNS, and liver, with 
reversal of central and somatic pathology in MPS IIIA mice leading 
to full correction of behavioral deficits and substantially extended 
lifespan. Long-term expression of the therapeutic gene is fundamen-
tal to achieving full correction of the pathological accumulation of 
GAGs. These results are fully translatable to a large animal model, 
showing long-term expression of the species-specific transgene and 
similar transgene biodistribution to mice when vector was delivered 
using a procedure commonly used in pediatric neurosurgery. Our 
results provide strong evidence supporting the clinical translation of 
this approach to treat MPS IIIA and other LSDs affecting the CNS.
Methods
Animals. Congenic C57Bl/6 mice carrying an inactivating amino acid 
change (D31N) in the sulfamidase gene were used (5). Affected MPS IIIA 
and healthy littermates were bred from heterozygous founders (The Jack-
son Laboratory). Genotyping was performed as previously described (5). 
notype, which was attributed to the late initiation of treatment 
(61). In our study, 4 months after i.c. administration of AAV9-Sgsh 
vectors to 2-month-old mice, i.e. mice at 6 months of age, the 
animals showed normal CNS GAG content and no signs of lys-
osomal distention or neuroinflammation, suggesting that con-
stant local production of the enzyme might be more efficient 
in reversing established disease. Moreover, at 12 to 14 months 
of age, i.e., an age at which untreated MPS IIIA mice are dying, 
brain GAG content remained normal in treated MPS IIIA male 
and female mice that received a single administration of vector 
10–12 months beforehand. The observation, in both genders, 
of complete GAG normalization in caudal sections of the brain 
that had shown partial reductions when evaluated 4 months 
after treatment, suggests that these areas require sustained sul-
famidase production over a prolonged period of time to be fully 
corrected, a result never described in prior studies and that has 
important implications for the design of future clinical trials for 
both gene transfer and ERT approaches to treating MPS IIIA and 
other lysosomal storage disorders. Normalization of GAG con-
tent was associated with normal behavior and lifespan, indica-
Figure 9
Intracerebroventricular administration of AAV9 vectors to dogs. Healthy adult beagle dogs (Dogs 11 and 12) received a unilateral i.c.v. injection 
of 2 × 1013 vg of AAV9-GFP vectors. (A) Representative software screenplay depicting the neuronavigator-guided trajectory used by the neuro-
surgeon to reach the lateral ventricle from the surface of the skull. (B) Transgene expression in Dog 12 was analyzed by immunohistochemistry 
8 days after administration. Expression was detected throughout the CNS (see diagram) and PNS (indicated by transduction of dorsal root gan-
glia) following i.c.v. delivery of AAV9 vectors to the CSF. LV, lateral ventricle; IVv, fourth ventricle; TC, temporal cortex; PL, piriform lobe; DRG, 
dorsal root ganglia. Scale bars: 250 μm.
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and the skin of the posterior part of the head, from behind the ears 
to approximately between the scapulae, was shaved. Mice were held in 
a prone position, with the head at a slightly downward inclination. A 
2-mm rostro-caudal incision was made to introduce a Hamilton syringe 
at an angle of 45° to 55° into the cisterna magna, between the occiput 
and the C1 vertebra, and 5 μl of vector dilution was injected. Given 
that the CNS was the main target compartment for vector delivery, the 
mice were dosed with the same number of vector genomes per mouse, 
irrespective of gender or body weight. In dogs, anesthesia started with 
premedication with 0.02 mg/kg of i.v. buprenorphine hydrochloride 
(Buprex; Schering-Plough). Thirty minutes later, induction was per-
formed with i.v. administration of 4 mg/kg of propofol (PropoVet; B. 
Braun Medical) and 0.5 mg/kg of diazepam. After endotracheal intu-
bation, anesthesia was maintained by inhalation of 2% isoflurane 
(IsoVet; B. Braun) in 100% oxygen. With the dog positioned in lateral 
recumbency, a 22-gauge needle was introduced into the cisterna magna 
between the occipital bone and the C1 vertebra. A syringe connected to a 
Mice were fed a standard diet ad libitum (Harlan Teklad) and were main-
tained under a 12-hour light-dark cycle. Healthy male beagle dogs were 
purchased from Isoquimen or Marshall BioResources. Animals were fed 
individually once daily at 9:00 am with 30 g/kg of body weight of standard 
dry food (Elite Nutrition; Nestle).
Recombinant AAV vectors. AAV expression cassettes were generated 
by cloning the cDNA of murine sulfamidase (clone ID: D330015N16; 
RIKEN), optimized human sulfamidase (GeneArt; Life Technologies), or 
GFP under the control of the ubiquitous CAG promoter (hybrid of the 
chicken β-actin promoter and CMV enhancer) into single-stranded AAV 
backbone plasmids. The GFP constructs also contained the WPRE ele-
ment to enhance expression. AAV vectors were produced by helper virus-
free transfection of HEK293 cells and purified using an optimized cesium 
chloride gradient–based purification protocol that renders vector preps of 
high purity and devoid of empty capsids (68).
Vector administration. For i.c. delivery in mice, animals were anesthe-
tized by i.p. injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), 
Figure 10
Comparison of i.c. and i.c.v. routes of AAV9 delivery. (A and B) Vector gene copy number and GFP mRNA expression were compared in 3 dogs 
following CSF delivery of 2 × 1013 vg of AAV9-GFP vectors through either an i.c. (Dog 10) or i.c.v. (Dogs 11 and 12) route. Analysis of samples 
representative of the whole CNS and PNS (A) and somatic tissues (B). md, medial; dr, dorsal; lt, lateral; vn, ventral; cn, central; R, right; L, left; 
cv-an, cervical anterior; cv-cd, cervicocaudal; I, intumescence; cv-th, cervicothoracic; th-an, thoracic anterior; th-md, thoracic medial; th-cd, 
thoracic caudal; ls, lumbosacral; ceq, cauda equina; drg, dorsal root ganglia; lm, lumbar; th, thoracic; cv, cervical. vg/dg, vector genome/diploid 
genome; IC, intracisternal; ICV, intracerebroventricular.
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fluid extension catheter tube with a 3-way stopcock was attached to the 
needle for delivery of 1 ml of total volume over a period of 15 seconds 
(fast) or 10 minutes (slow), with the assistance of an infusion pump 
(Harvard Apparatus). For i.c.v. injection, anesthetized dogs were sub-
jected to presurgical magnetic resonance imaging to establish brain 
coordinates. An image-based neuronavigation system (Stealthstation 
AxiEM; Medtronic) was used to guide the placement of a 2.5-mm-diam-
eter Teflon catheter into the lateral ventricle via a small burr hole made 
through the parietal bone. Throughout all surgical procedures, temper-
ature, cardiac and respiratory frequency, capnography, arterial pressure, 
pulse, and electrocardiography were monitored using a multifunctional 
patient Vet Care monitor (B. Braun).
Sulfamidase activity and GAG quantification. Four months after injec-
tion, the mice were anesthetized with ketamine and xylazine, blood 
was extracted by cardiac puncture, and the animals were intracardially 
perfused with 10 ml of PBS to completely clear blood from the tissues. 
Brain and tissue samples were sonicated in 500 μl of water, and sul-
famidase activity was assayed in supernatants with a 2-step protocol 
using a 4-methylumbelliferone–derived ﬂuorogenic substrate (4-MU; 
Moscerdam Substrates), as previously described (69). Briefly, the first 
step consisted of the incubation of 30 μg of tissue protein extract or 10 μl 
of serum or CSF, with 10 mmol per liter of 4-MU-αGIcNS for 17 hours 
at 47°C. The second incubation was carried out in the presence of 
10 U/ml of α-glucosidase (Sigma-Aldrich) in 0.2% BSA for 24 hours 
at 37°C. After stopping the reaction, the released fluorescence was mea-
sured. When indicated, sulfamidase activity was normalized against 
total protein content quantified by a Bradford assay (Bio-Rad). For GAG 
quantification, samples were weighed and digested with proteinase K, 
and extracts were clarified by centrifugation and filtration (Ultrafree 
MC; Millipore). A Blyscan sulfated glycosaminoglycan kit (Biocolor 
Life Science Assays) was used for GAG measurement using chondroitin 
4-sulfate as a standard. Results were normalized to wet tissue weight.
Histology and electron microscopy. Formalin-fixed, paraffin-embedded 
tissue sections were incubated overnight at 4°C with rat anti-LAMP1 
(SC-1992; Santa Cruz Biotechnology); rabbit anti-LIMP2 (NB400; Novus 
Biologicals); rabbit anti-GFAP (Z0334; Dako Cytomation); goat anti-GFP 
(Ab6673; Abcam); chicken anti-GFP (Ab13970; Abcam); mouse anti-NeuN 
(MAB377; Millipore); goat anti-IBA1 (Ab5076; Abcam); and mouse anti-
Figure 11
Impact of preexisting humoral immunity on CNS transduction following CSF vector delivery. (A) Immunodetection of GFP-expressing cells in 
the CNS following i.c. administration of 2 × 1013 vg of AAV9-GFP vectors to healthy adult beagle dogs with preimmunity against AAV9 (Dogs 13 
and 14). FC-Lepto, frontal cortex leptomeninges; OC-Lepto, occipital cortex leptomeninges; OC, occipital cortex; IVv-CPl, fourth ventricle choroid 
plexus; IVv-Epen, fourth ventricle ependimocytes; Pin, pineal gland; SC-Ceq, spinal cord cauda equina. Scale bars: 200 μm and 100 μm (insets). 
(B) Vector genome copy number and GFP mRNA expression following intra-CSF delivery of 2 × 1013 vg of AAV9-GFP vectors to naive (Dog 10) 
or preimmunized (Dogs 13 and 14) dogs. Samples are representative of the whole CNS.
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GCCTGTGTTGCC-3′. The final values were determined by comparison 
with a reference standard curve built from serial dilutions of the linear-
ized plasmids bearing the GFP expression cassette spiked into 20 ng or 
100 ng of nontransduced genomic DNA. Total RNA was purified from 
tissues homogenized in TriPure Isolation Reagent (Roche) using an 
RNeasy Mini kit (QIAGEN). cDNA was synthesized with a Transcriptor 
First Strand cDNA Synthesis kit (Roche). Quantitative PCR was performed 
using a Light Cycler 480 Probes Master (Roche) with GFP-specific primers 
and probe. Forward primer: 5′-AGCTGGACGGCGACGTAA-3′; reverse 
primer: 5′-GTGCAGATGAACTTCAGGGTCA-3′; probe: 5′-CGTGTCCGG-
CGAGGGCGA-3′ (Invitrogen). These were normalized to the expression of 
the dog RPLP0 gene: forward primer: 5′-GCTGCTGGCCAATAAGGTT-3′; 
reverse primer: GGGCTGGCACAGTGACTT-3′.
Anti-AAV antibody determination. Anti-AAV2 and AAV9 NAb titers were 
determined in human and dog CSF and serum samples as previously 
described (42) using an in vitro neutralization assay. An AAV self-com-
plementary vector expressing the Renilla luciferase reporter gene under 
the control of the chicken β-actin promoter (scAAV-Luc) was used in the 
assay. To increase the efficiency of AAV vector transduction in vitro, 2V6.11 
cells (ATCC) were used, which expressed the adenoviral gene E4 under the 
control of an inducible promoter. Cells were seeded in a 96-well plate at 
a density of 1.25 × 104 cells per well, and a 1:1,000 dilution of ponaster-
one A (Invitrogen) was added to the medium to induce E4 expression. 
On the day of assay, serial dilutions of heat-inactivated test serum were 
mixed with medium containing vector. Residual activity of the reporter 
transgene was measured using a luminometer.
Statistics. All results are expressed as the mean ± SEM. Statistical com-
parisons were made using 1-way analysis of variance (ANOVA), and multi-
ple comparisons between control and treatment groups were made using 
Dunnett’s post test. A P value less than 0.05 was considered statistically 
significant. The Kaplan–Meier method was used to analyze survival, and 
the log-rank test was used for comparisons.
MAC2 (CL8942AP; Cedarlane) antibodies; and BSI-B4 lectin (L5391; 
Sigma-Aldrich). The secondary antibodies were: biotinylated rabbit anti-
rat IgG (E0467; Dako) or biotinylated goat anti-rabbit IgG (31820; Vector 
Laboratories). Bright-field sections were stained with 3.3-diaminoben-
zidine (Sigma-Aldrich) and counterstained with hematoxylin. Images 
were obtained with an Eclipse E800 optical microscope (Nikon). For 
immunofluorescence, streptavidin-conjugated Alexa 488 (S-11223; Molecu-
lar Probes) or streptavidin-Alexa 568 (S-11226; Molecular Probes) was used 
for visualization. TO-PRO-3 (Invitrogen) was used to counterstain nuclei. 
Signal intensity was quantified with images obtained using a confocal 
microscope (Leica Microsystems). NIS Elements Advanced Research 2.20 
software was used to quantify GFP, LIMP2, GFAP, and BSI-B4 signals in 3 
to 5 images (original magnification, ×20) per animal of each brain region, 
using the same signal threshold settings for all animals. Then, the percent-
age of positive area was calculated, i.e., the area, in pixels, with a positive 
signal over the total tissue area in the image. For transmission electron 
microscopy, samples were processed as previously described (33) and exam-
ined with a Hitachi H-7000 transmission electron microscope (Hitachi).
Open field test. The open field test was performed in 6-month-old mice 
between 9:00 am and 1:00 pm. Animals were placed in the center of a 
brightly lit chamber (41 × 41 × 30 cm) crossed by 2 bundles of photobeams 
(LE 8811; Panlab) that detect horizontal and vertical movements. Three 
squared concentric regions were delimited in the arena: center (14 × 14 cm), 
periphery (27 × 27 cm), and border (41 × 41 cm). Motor and exploratory 
activities were evaluated during the first 3 minutes. The total number of 
rearings and total number of lines crossed were recorded by photobeam 
disruption (SesaCom32; Panlab). The total distance covered was evaluated 
using a video tracking system (SMART Junior; Panlab).
Vector genome copy number and transgenic expression. Total DNA was iso-
lated with a MasterPureDNA Purification Kit (Epicentre) from overnight 
tissue digestions in proteinase K (0.2 mg/ml). The vector genome copy 
number in 20 or 100 ng of total DNA was determined by quantitative 
PCR with primers and probe specific for the WPRE element in the AAV-
GFP vector. Forward primer: 5′-CGGCTGTTGGGCACTGA-3′; reverse 
primer: 5′-GGAAGGTCCGTCGAATTGA-3′; probe: 5′-ATGGCTGCTC-
Table 3
NAb titers in human-matched serum and CSF samples
Patient Age Sample AAV9 NAb AAV2 NAb
Healthy 1 4 d Serum 1:1 1:10–1:31.6
  CSF 1:1–1:3.1 1:1–1:3.1
Healthy 2 1 mo Serum 1:1 1:1
  CSF 1:1–1:3.1 1:1
Healthy 3 1 yr Serum 1:10–1:31.6 1:100–1:316
  CSF 1:1–1:3.1 1:1
Healthy 4 4 yr Serum 1:1 1:1–1:3.1
  CSF 1:1–1:3.1 1:1
Healthy 5 5 yr Serum 1:1 1:1
  CSF 1:1–1:3.1 1:1–1:3.1
MPS IIIA-1 6 yr Serum 1:1–1:3.1 1:3.1–1:10
  CSF 1:1–1:3.1 1:1–1:3.1
MPS IIIA-2 7 yr Serum 1:31.6–1:100 1:316–1:1,000
  CSF 1:1–1:3.1 1:1–1:3.1
MPS IIIA-3 7 yr Serum 1:100–1:316 1:1,000–1:3,160
  CSF 1:1–1:3.1 1:3.1–1:10
MPS IIIA-4 12 yr Serum 1:316–1:1,000 1:1,000–1:3,160
  CSF 1:3.1–1:10 1:3.1–1:10
Anti-AAV9 and AAV2 vector NAb titers determined in matched serum 
and CSF samples from healthy and MPS IIIA–affected children.
Table 4
Follow up of NAb titers before and after intra-CSF delivery of 
AAV9 vectors to dogs
Dog no. Sample Days after injection
  0 8
1 Serum 1:3–1:10 NA
 CSF NA 1:1–1:3.1
2 Serum 1:3.1–1:10 >1:3,160
 CSF 1:1–1:3.1 1:1–1:3.1
3 Serum 1:3.1–1:10 >1:3,160
 CSF 1:1–1:3.1 1:1–1:3.1
4 Serum NA >1:3,160
 CSF 1:1–1:3.1 1:1–1:3.1
10 Serum <1:1 >1:1,000
 CSF 1:1–1:3.1 1:1–1:10
11 Serum <1:1 >1:1,000
 CSF 1:1–1:3.1 1:1–1:10
12 Serum <1:1 >1:1,000
 CSF 1:1–1:3.1 1:1–1:10
13A Serum 1:100–1:1,000 >1:1,000
 CSF 1:1–1:3.1 ND
14A Serum 1:100–1:1,000 >1:1,000
 CSF 1:1–1:3.1 1:1–1:10
ND, sample not determined. AFor preimmunized dogs, the “0” time point 
corresponds to samples obtained before i.c. administration, i.e., 30 days 
after immunization with i.v. delivery of 1.2 × 1012 vg of AAV9-null vector.
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